NASDAQ$SDGR
Schrodinger Inc/United States · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported strong third quarter results with total revenue growth driven by drug discovery portfolio progress, narrowed full-year revenue guidance with mix shifting toward drug discovery, and advanced clinical and preclinical programs.
Schrödinger reported a strong third quarter with software revenue in line with expectations and strong drug discovery revenue. The company initiated a Phase 1 study for its MALT1 program and is preparing to present new preclinical data from its CDC7 program. The company's total revenue increased by 24% compared to Q3 2021.
- Total revenue increased by 24% year-over-year, reaching $37.0 million.
- Drug discovery revenue saw a significant increase of 121% compared to the same quarter last year, amounting to $12.3 million.
- Initiated Phase 1 clinical trial of MALT1 inhibitor, SGR-1505, for patients with relapsed or refractory B-cell malignancies.
- New preclinical data for CDC7 inhibitor, SDGR-2921, will be presented at the American Society of Hematology 2022 Annual Meeting.
Headline financials
Revenue & EPS history
Schrodinger · Revenue · Quarterly
$37M
Revenue by segment
Schrodinger · $37M total across 2 segments · Q3 2022
- Software Products & Services$24.7M+1.6%66.7%
- Drug Discovery$12.3M+121.1%33.3%
Forward guidance
Schrödinger narrowed its total revenue guidance for 2022 to a range of $167 million to $175 million, representing growth of 21% to 27% over 2021. The company expects software revenue to range from $122 million to $127 million and drug discovery revenue to range from $45 million to $48 million.
Tailwinds
- Total revenue is now expected to range from $167 million to $175 million, representing growth of 21 percent to 27 percent over 2021.
- Total software revenue is now expected to range from $122 million to $127 million, representing eight percent to 12 percent growth over 2021.
- Total drug discovery revenue is now expected to range from $45 million to $48 million, representing 82 percent to 94 percent growth over 2021.
- Software gross margin percentage is still expected to be in the mid-70s.
- Operating expense growth is now expected to be approximately 40 percent for 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-2.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+1.8%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+31.4%
Q4 2021
Best reaction
-29.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +1.9% | +23.0% | |
| Q4 2025 | +8.3% | +5.9% | -6.1% | |
| Q3 2025 | -5.8% | -7.4% | -10.8% | |
| Q1 2025 | +0.6% | +0.2% | +3.8% | |
| Q4 2024 | +2.5% | -2.9% | -8.0% | |
| Q3 2024 | +13.1% | -5.1% | +7.8% | |
| Q2 2024 | +0.1% | -15.7% | -6.8% | |
| Q1 2024 | -4.9% | -1.4% | -11.7% | |
| Q4 2023 | -23.1% | -23.7% | -18.4% | |
| Q3 2023 | +15.3% | +27.5% | +49.7% | |
| Q2 2023 | -26.9% | -27.3% | -29.8% | |
| Q1 2023 | -5.1% | -6.4% | +22.3% | |
| Q4 2022 | +14.5% | +21.7% | +16.8% | |
| Q3 2022 | -14.6% | -15.6% | -29.2% | |
| Q2 2022 | +1.5% | -4.9% | -19.1% | |
| Q1 2022 | -5.5% | -10.5% | +1.5% | |
| Q4 2021 | +31.4% | +45.4% | +36.4% | |
| Q3 2021 | -16.1% | -15.6% | -31.6% | |
| Q2 2021 | -5.1% | -12.1% | -0.1% | |
| Q1 2021 | -6.8% | -4.3% | +19.4% | |
| Q4 2020 | -29.9% | -29.7% | -20.8% | |
| Q3 2020 | +12.4% | +15.8% | +39.6% | |
| Q3 2019 | +12.4% | +15.8% | +39.6% | |
| Q2 2020 | -2.5% | -2.4% | -24.2% | |
| Q1 2020 | -8.1% | +0.5% | +3.0% | |
| Q4 2019 | -14.6% | +8.3% | +1.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro